STXS

Stereotaxis, Inc. Q1 2011 10-Q Summary

Business Context and Reporting Period

This report covers the quarterly period ended March 31, 2011. Stereotaxis, Inc. designs, manufactures, and markets the NIOBE magnetic navigation system and the ODYSSEY Enterprise Solution for interventional cardiology procedures. The company is a non-accelerated filer with 55,337,295 shares of common stock outstanding as of April 29, 2011.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Decline: Total revenue decreased 4% year-over-year. System revenue dropped 18% (from $5.23M to $4.29M) due to fewer NIOBE system sales (one unit sold in Q1 2011 vs. four in Q1 2010). Conversely, revenue from disposables, service, and accessories increased 10% to $5.94 million, driven by a larger installed base.
• Margin Compression: Overall gross margin decreased to 71% from 73%. System gross margin fell to 49% from 60% due to a product mix shift toward lower-margin ODYSSEY systems. Disposable/service margins improved to 86% from 84%.
• Expense Growth: Operating expenses increased 15% to $15.98 million. Sales and marketing expenses rose 25% to $8.34 million due to increased headcount to drive utilization. General and administrative expenses increased 9% to $4.25 million.
• Liquidity Position: Working capital decreased significantly from $12.4 million to $2.8 million, primarily due to cash burn from operations. Cash on hand decreased by $4.85 million during the quarter.
• Debt Levels: Total debt increased to $33.5 million. The company drew an additional $6.1 million net on its revolving line of credit during the quarter. The Biosense Webster advance balance remained approximately $6.4 million.

Outlook, Risks, and Management Commentary

• Cash Flow Outlook: Management expects negative cash flow from operations to continue throughout 2011. The company anticipates increased sales, marketing, and general administrative expenses to support commercialization.
• Liquidity Sufficiency: Management believes existing cash, cash equivalents, and borrowing facilities (including $2.4 million remaining availability on the revolving line) are sufficient to fund operations for the next 12 months. However, additional financing may be required, which could be dilutive.
• Debt Covenants: The company is in compliance with all covenants of its bank loan agreement as of March 31, 2011. The revolving credit facility matures in March 2012.
• Strategic Collaboration: In May 2011 (subsequent event), the company entered a new strategic collaboration with Biosense Webster granting them global, non-exclusive rights to resell Odyssey products.
• Risks: Key risks include the need for additional financing, foreign exchange exposure (18% of revenue in foreign currencies), and the requirement to repay the Biosense Webster advance by December 31, 2011, or upon an "Accelerating Recoupment Event" (e.g., raising $50 million in equity).

Investor Verification Checklist

• Verify the company's ability to repay the $6.4 million Biosense Webster advance due by December 31, 2011, given the current cash burn rate.
• Monitor the utilization of the remaining $2.4 million borrowing capacity on the revolving credit line.
• Assess the impact of the product mix shift (fewer NIOBE systems, more ODYSSEY systems) on long-term gross margin stability.
• Review the terms of the new May 2011 collaboration with Biosense Webster for potential revenue recognition changes or royalty implications.
• Track the company's compliance with "tangible net worth" and liquidity covenants in the credit agreement.